{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"119.0"},{"groupId":"OG001","spread":"11.0","value":"96.5"},{"groupId":"OG002","value":"107.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.0"},{"groupId":"OG001","spread":"12.3","value":"97.6"},{"groupId":"OG002","spread":"2.1","value":"109.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"title":"Prior to Maintenance Therapy"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.2","value":"105.3"},{"groupId":"OG001","spread":"15.2","value":"100.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Completion of Therapy"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.8","value":"96.8"},{"groupId":"OG001","spread":"13.3","value":"93.1"},{"groupId":"OG002","value":"71.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"title":"12 Months Off Therapy"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.6","value":"98.4"},{"groupId":"OG001","spread":"15.3","value":"90.2"},{"groupId":"OG002","spread":"13.3","value":"89.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"24 Months Off Therapy"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.8","value":"101.6"},{"groupId":"OG001","spread":"20.2","value":"89.7"},{"groupId":"OG002","spread":"12.4","value":"89.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"25"},{"groupId":"OG002","value":"4"}],"units":"Participants"}],"title":"36 Months Off Therapy"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.9","value":"93.2"},{"groupId":"OG001","spread":"14.7","value":"87.6"},{"groupId":"OG002","spread":"17.0","value":"78.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"48 Months Off Therapy"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"36.2","value":"86.3"},{"groupId":"OG001","spread":"17.1","value":"84.6"},{"groupId":"OG002","value":"65.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"title":"60 Months Off Therapy"}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"49"},{"groupId":"OG002","value":"9"}],"units":"Participants"}],"description":"Scores measuring processing speed were obtained based on the visual matching standard score from the Woodcock Johnson III instrument. Higher scores indicate better performance. The normative mean is 100 with a standard deviation of 15.","dispersionType":"Standard Deviation","groups":[{"description":"Patients with gross total resection (GTR)/no evidence of metastatic (M0) medulloblastoma, nodular desmoplastic or high grade glioma histology will receive induction chemotherapy and low-risk therapy.","id":"OG000","title":"Low-Risk Group"},{"description":"Patients with M0 medulloblastoma or nodular desmoplastic histology with less than a GTR, other histologic diagnoses with no metastatic disease, will receive induction chemotherapy and intermediate-risk therapy.","id":"OG001","title":"Intermediate-Risk Group"},{"description":"Patients with central nervous system (CNS) metastatic disease will receive induction chemotherapy and high-risk therapy.","id":"OG002","title":"High-Risk Group"}],"paramType":"MEAN","populationDescription":"Eligible patients with scores at any of the data collection timepoints were included. Sample sizes differ across timepoints as not all subjects had scores for all timepoints.","reportingStatus":"POSTED","timeFrame":"Baseline, prior to maintenance therapy, completion of therapy, and 12 months, 24 months, 36 months, 48 months, and 60 months off therapy","title":"Neurocognitive Performance Related to Processing Speed as Measured by Visual Matching Standard Scores","type":"SECONDARY","unitOfMeasure":"score on a scale"}